Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study.
chemoradiation
cisplatin
radiation
taxane
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
20
11
2019
revised:
20
02
2020
accepted:
10
03
2020
pubmed:
27
3
2020
medline:
22
6
2021
entrez:
27
3
2020
Statut:
ppublish
Résumé
There is little data describing neurocognitive late sequelae in patients treated for oropharyngeal cancer. Using PROs, scores for "numbness/tingling" and "difficulty remembering" were assessed. Wilcoxon testing was utilized to compare mean assessment scores (1-10) between treatment subgroups. Four-hundred ninety-seven patients were evaluated and 267 (54%) received chemotherapy. The mean score for numbness/tingling for patients receiving radiation alone was 0.99 and for each chemotherapy subgroup were: Induction chemotherapy (IC), 1.35 (n = 99); concurrent chemotherapy (CCRT), 1.04 (n = 111) and IC + CCRT, 2.48 (n = 57); 30% of patients who received IC + CCRT had scores ≥5. The mean scores for difficulty remembering were XRT: 1.44, chemotherapy: 1.45, and IC + CCRT subgroup: 2.42. The symptom burden related to peripheral neuropathy and cognitive complaints was minimal. A minority of patients reported high burdens. Particularly, 30% of patients receiving IC + CCRT described moderate to severe numbness/tingling.
Sections du résumé
BACKGROUND
There is little data describing neurocognitive late sequelae in patients treated for oropharyngeal cancer.
METHODS
Using PROs, scores for "numbness/tingling" and "difficulty remembering" were assessed. Wilcoxon testing was utilized to compare mean assessment scores (1-10) between treatment subgroups.
RESULTS
Four-hundred ninety-seven patients were evaluated and 267 (54%) received chemotherapy. The mean score for numbness/tingling for patients receiving radiation alone was 0.99 and for each chemotherapy subgroup were: Induction chemotherapy (IC), 1.35 (n = 99); concurrent chemotherapy (CCRT), 1.04 (n = 111) and IC + CCRT, 2.48 (n = 57); 30% of patients who received IC + CCRT had scores ≥5. The mean scores for difficulty remembering were XRT: 1.44, chemotherapy: 1.45, and IC + CCRT subgroup: 2.42.
CONCLUSIONS
The symptom burden related to peripheral neuropathy and cognitive complaints was minimal. A minority of patients reported high burdens. Particularly, 30% of patients receiving IC + CCRT described moderate to severe numbness/tingling.
Identifiants
pubmed: 32212359
doi: 10.1002/hed.26151
pmc: PMC7519845
mid: NIHMS1630938
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2137-2144Subventions
Organisme : NCI NIH HHS
ID : P50 CA097007
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE025248
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214825
Pays : United States
Organisme : NIBIB NIH HHS
ID : R25 EB025787
Pays : United States
Organisme : NIDCR NIH HHS
ID : R56 DE025248
Pays : United States
Organisme : NIDCR NIH HHS
ID : 1R01DE025248/R56DE025248
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218148
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
N Engl J Med. 2007 Oct 25;357(17):1695-704
pubmed: 17960012
N Engl J Med. 2007 Oct 25;357(17):1705-15
pubmed: 17960013
Cancer. 2004 Aug 1;101(3):466-75
pubmed: 15274059
JAMA Otolaryngol Head Neck Surg. 2018 Jan 1;144(1):71-79
pubmed: 29167901
Toxics. 2015 Apr 28;3(2):152-169
pubmed: 29056655
Gynecol Oncol. 2014 Dec;135(3):510-7
pubmed: 25281491
Anticancer Drugs. 1995 Jun;6(3):369-83
pubmed: 7670134
J Clin Oncol. 2008 Jul 1;26(19):3138-46
pubmed: 18474879
Head Neck. 2007 Oct;29(10):923-31
pubmed: 17358040
J Clin Oncol. 2014 Sep 1;32(25):2735-43
pubmed: 25049329
Pract Radiat Oncol. 2017 Jul - Aug;7(4):246-253
pubmed: 28428019
J Clin Oncol. 2003 Sep 1;21(17):3194-200
pubmed: 12860964
Lancet Oncol. 2017 Jun;18(6):803-811
pubmed: 28434660
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
J Clin Oncol. 2017 Feb 10;35(5):490-497
pubmed: 28029303
Lancet Oncol. 2013 Mar;14(3):257-64
pubmed: 23414589